Chemotherapy-Induced Neutropenia (CIN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chemotherapy-Induced Neutropenia (CIN) Market Outlook
Thelansis’s “Chemotherapy-Induced
Neutropenia (CIN) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Chemotherapy-Induced
Neutropenia (CIN) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Chemotherapy-Induced Neutropenia (CIN)
Overview
Neutropenia
is a severe adverse effect frequently associated with cancer chemotherapy. Loss
of neutrophils disrupts immune defense mechanisms and increases the likelihood
of infections. Infections lead to fever, known as febrile neutropenia (FN).
Neutrophils generally comprise approximately half to two-thirds of all white
blood cells (immune cells) and protect against bacterial infections. Patients
who develop neutropenia may have a higher-than-normal risk of infections, and
the severity of subsequent infections is also higher. Chemotherapeutic agents
act on the bone marrow, where active cell division occurs, and deplete
hematopoietic stem cells, leading to a decreased circulating absolute
neutrophil count. Patients receiving chemotherapy have been reported to
experience a temporary reduction in their neutrophil counts.
Chemotherapy-induced neutropenia (CIN) remains a common dose-limiting toxicity
for chemotherapeutic agents, causing treatment delays and/or dose reductions.
According to this grading system, neutropenia is classified according to the
following four grades: (i) Grade 1 with an ANC of 1,500–2,000 cells/mm3, (ii)
Grade 2 with an ANC of 1,000–1,500 cells/mm3, (iii) Grade 3 with an ANC of
500–1,000 cells/mm3, and (iv) Grade 4 with an ANC < 500 cells/mm3.
Currently, the standard chemotherapy-induced neutropenia treatment uses a
granulocyte colony-stimulating factor (G-CSF) to attenuate white blood cell
counts and absolute neutrophil counts (ANCs). G-CSFs are frequently used to
decrease the incidence and duration of chemotherapy-induced neutropenia.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment